• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

来自晚期印度患者的新型皮肤鳞状细胞癌细胞系的建立与分子特征分析

Establishment and molecular characterization of the novel cutaneous squamous cell carcinoma cell line from advanced-stage Indian patient.

作者信息

Mehta Darshan, Paradkar Akshay, Nayak Prakash, Rekhi Bharat, Mohanty Bhabani, Chaudhari Pradip, Waghmare Sanjeev K

机构信息

Stem Cell Biology Group, Waghmare Lab, Cancer Research Institute, Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai, Maharashtra, 410210, India.

Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai, 400085, India.

出版信息

Hum Cell. 2025 May 25;38(4):108. doi: 10.1007/s13577-025-01237-4.

DOI:10.1007/s13577-025-01237-4
PMID:40413685
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12104104/
Abstract

Cutaneous squamous cell carcinoma (CSCC) is the second most prevalent skin cancer with low metastatic potential; it poses significant morbidity challenges. CSCC possesses significant heterogeneity and the treatment presents a formidable challenge. To gain a clear insight into the diverse nature of these tumors, the development of an in vitro cell line model is essential. However, there are few cell lines that were established, and only one skin SCC cell line is available on the ATCC. In the present study, we established and characterized a novel ACSCC1 cell line from the advanced-stage treatment naïve cutaneous SCC originating from the forearm of the Indian patient. The keratin expression profile showed the epithelial origin of the cell line, ploidy and karyotyping revealed the hyperdiploid population; ACSCC1 showed an increased tumorigenic and metastatic potential. Further, our cell line showed higher invasive, migratory potential and epithelial-mesenchymal-transition (EMT). Additionally, the Transmission electron microscopy (TEM) results showed an aberrant mitochondrial morphology and reduction in the cellular junctions. Further, our whole genome sequencing (WGS) analysis showed mutations in the cancer-related genes. Overall, the novel ACSCC1 cell line can be used to decipher the molecular signaling in the cancer stem cells (CSCs); targeting the CSCs population may help in understanding the tumor recurrence.

摘要

皮肤鳞状细胞癌(CSCC)是第二常见的皮肤癌,转移潜力低;它带来了重大的发病挑战。CSCC具有显著的异质性,其治疗面临巨大挑战。为了深入了解这些肿瘤的多样性本质,建立体外细胞系模型至关重要。然而,已建立的细胞系很少,且美国典型培养物保藏中心(ATCC)仅有一种皮肤鳞状细胞癌细胞系。在本研究中,我们从一名印度患者前臂的晚期未经治疗的皮肤鳞状细胞癌中建立并鉴定了一种新型ACSCC1细胞系。角蛋白表达谱显示了该细胞系的上皮来源,倍性和核型分析揭示了超二倍体群体;ACSCC1表现出增加的致瘤和转移潜力。此外,我们的细胞系显示出更高的侵袭、迁移潜力以及上皮-间质转化(EMT)。另外,透射电子显微镜(TEM)结果显示线粒体形态异常且细胞连接减少。此外,我们的全基因组测序(WGS)分析显示癌症相关基因存在突变。总体而言,新型ACSCC1细胞系可用于解读癌症干细胞(CSCs)中的分子信号;靶向CSCs群体可能有助于理解肿瘤复发。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67c5/12104104/3ece4b76033c/13577_2025_1237_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67c5/12104104/624f94586f22/13577_2025_1237_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67c5/12104104/29871ffb3d03/13577_2025_1237_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67c5/12104104/739b60cbc2be/13577_2025_1237_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67c5/12104104/dc48d91e5018/13577_2025_1237_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67c5/12104104/3ece4b76033c/13577_2025_1237_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67c5/12104104/624f94586f22/13577_2025_1237_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67c5/12104104/29871ffb3d03/13577_2025_1237_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67c5/12104104/739b60cbc2be/13577_2025_1237_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67c5/12104104/dc48d91e5018/13577_2025_1237_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67c5/12104104/3ece4b76033c/13577_2025_1237_Fig5_HTML.jpg

相似文献

1
Establishment and molecular characterization of the novel cutaneous squamous cell carcinoma cell line from advanced-stage Indian patient.来自晚期印度患者的新型皮肤鳞状细胞癌细胞系的建立与分子特征分析
Hum Cell. 2025 May 25;38(4):108. doi: 10.1007/s13577-025-01237-4.
2
Establishment and characterization of patient-derived tongue squamous cell carcinoma cell lines.患者来源的舌鳞状细胞癌细胞系的建立与鉴定
Hum Cell. 2025 May 20;38(4):102. doi: 10.1007/s13577-025-01231-w.
3
Sun protection for preventing basal cell and squamous cell skin cancers.预防基底细胞癌和鳞状细胞皮肤癌的防晒措施。
Cochrane Database Syst Rev. 2016 Jul 25;7(7):CD011161. doi: 10.1002/14651858.CD011161.pub2.
4
St Andrews Referral Delay in Skin Cancer (StARDISC): a study of keratinocyte skin cancer time to treatment, growth, invasiveness, British Association of Dermatologists risk factors and excision adequacy.圣安德鲁斯皮肤癌转诊延迟研究(StARDISC):一项关于角质形成细胞皮肤癌治疗时间、生长、侵袭性、英国皮肤科医师协会危险因素及切除充分性的研究。
Br J Dermatol. 2025 Jun 20;193(1):157-166. doi: 10.1093/bjd/ljaf097.
5
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
6
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
7
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.紫杉烷类单药治疗方案用于复发性上皮性卵巢癌。
Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD008766. doi: 10.1002/14651858.CD008766.pub3.
8
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
9
p62 mRNA suppresses NLRP1 expression in cutaneous SCC cells through miR-34a-5p.p62信使核糖核酸通过微小核糖核酸-34a-5p抑制皮肤鳞状细胞癌细胞中NLRP1的表达。
Cell Death Dis. 2025 Jul 1;16(1):465. doi: 10.1038/s41419-025-07785-9.
10
Targeting Drp1 inhibits ESCC progression via the ROS-PGC1-α-Nrf1/2 pathway.靶向动力相关蛋白1(Drp1)通过活性氧(ROS)-过氧化物酶体增殖物激活受体γ共激活因子1α(PGC1-α)-核因子E2相关因子1/2(Nrf1/2)途径抑制食管鳞状细胞癌(ESCC)进展。
J Transl Med. 2025 Jun 17;23(1):674. doi: 10.1186/s12967-025-06697-8.

本文引用的文献

1
Establishment and molecular characterization of HCB-541, a novel and aggressive human cutaneous squamous cell carcinoma cell line.建立并鉴定新型侵袭性人皮肤鳞状细胞癌细胞系 HCB-541。
Hum Cell. 2024 Jul;37(4):1170-1183. doi: 10.1007/s13577-024-01054-1. Epub 2024 Apr 3.
2
Epithelial-to-mesenchymal transition status correlated with ultrastructural features, and TP53 mutation in patient-derived oral cancer cell lines.上皮-间质转化状态与超微结构特征相关,以及患者来源的口腔癌细胞系中的 TP53 突变。
Mol Biol Rep. 2023 Oct;50(10):8469-8481. doi: 10.1007/s11033-023-08720-x. Epub 2023 Aug 28.
3
Secretory phospholipase (sPLA-IIA) regulates breast cancer stem cells differentiation and metastatic potential.
分泌型磷脂酶(sPLA-IIA)调节乳腺癌干细胞的分化和转移潜能。
Biochem Biophys Res Commun. 2023 Oct 15;677:98-104. doi: 10.1016/j.bbrc.2023.07.057. Epub 2023 Aug 4.
4
Advances in cutaneous squamous cell carcinoma.皮肤鳞状细胞癌的研究进展。
Nat Rev Cancer. 2023 Jul;23(7):430-449. doi: 10.1038/s41568-023-00583-5. Epub 2023 Jun 7.
5
The global, regional, national burden of laryngeal cancer and its attributable risk factors (1990-2019) and predictions to 2035.全球、区域、国家喉癌负担及其可归因危险因素(1990-2019 年)及对 2035 年的预测。
Eur J Cancer Care (Engl). 2022 Nov;31(6):e13689. doi: 10.1111/ecc.13689. Epub 2022 Aug 18.
6
Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25 years.全球非黑色素瘤皮肤癌疾病负担的变化趋势:1990 年至 2019 年及其 25 年后的预测水平。
BMC Cancer. 2022 Jul 30;22(1):836. doi: 10.1186/s12885-022-09940-3.
7
Association of TP53 and CDKN2A Mutation Profile with Tumor Mutation Burden in Head and Neck Cancer.头颈部癌症中 TP53 和 CDKN2A 突变谱与肿瘤突变负担的关联。
Clin Cancer Res. 2022 May 2;28(9):1925-1937. doi: 10.1158/1078-0432.CCR-21-4316.
8
Incidence of melanoma and nonmelanoma skin cancers in Indian and the global regions.印度和全球地区黑色素瘤和非黑色素瘤皮肤癌的发病率。
J Cancer Res Ther. 2021 Jul-Sep;17(4):906-911. doi: 10.4103/jcrt.JCRT_785_19.
9
Clinical Spectrum of Cutaneous Malignancies in Central India: A Retrospective Study.印度中部皮肤恶性肿瘤的临床谱:一项回顾性研究。
Indian J Dermatol. 2021 May-Jun;66(3):284-290. doi: 10.4103/ijd.IJD_543_19.
10
Author Correction: The incidence and clinical analysis of non‑melanoma skin cancer.作者更正:非黑色素瘤皮肤癌的发病率及临床分析
Sci Rep. 2021 Jul 28;11(1):15705. doi: 10.1038/s41598-021-94435-7.